Pharmacopeia/Eos Plan To Outlicense First Therapeutic By 2005
Executive Summary
Pharmacopeia plans to outlicense its first therapeutic candidate resulting from its merger with genomics firm Eos by 2005.
You may also be interested in...
Eos/Pharmacopeia merger terminated
Eos and Pharmacopeia will continue to jointly own all compounds developed from the December transfer of Eos' therapeutic antibody target AAB1 to Pharmacopeia following termination of merger plans (1"The Pink Sheet" Aug. 27, 2001, p. 28)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011